J. Praag

1.5k total citations · 1 hit paper
22 papers, 1.0k citations indexed

About

J. Praag is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiation. According to data from OpenAlex, J. Praag has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Radiation. Recurrent topics in J. Praag's work include Lung Cancer Research Studies (10 papers), Advanced Radiotherapy Techniques (8 papers) and Lung Cancer Diagnosis and Treatment (7 papers). J. Praag is often cited by papers focused on Lung Cancer Research Studies (10 papers), Advanced Radiotherapy Techniques (8 papers) and Lung Cancer Diagnosis and Treatment (7 papers). J. Praag collaborates with scholars based in Netherlands, United Kingdom and United States. J. Praag's co-authors include Harm van Tinteren, Suresh Senan, Sherif Y. El Sharouni, Corinne Faivre‐Finn, Joost J. Nuyttens, Astrid Keijser, M. Hatton, J. Knegjens, Ben J. Slotman and Mischa S. Hoogeman and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

J. Praag

22 papers receiving 999 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

2014 384 citations Ben J. Slotman, Harm van Tinteren et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Praag Netherlands	12	756	514	384	347	233	22	1.0k
J. Knegjens Netherlands	12	599 0.8×	522 1.0×	247 0.6×	360 1.0×	237 1.0×	28	1.0k
Slobodan Milisavljević Serbia	18	1.0k 1.4×	880 1.7×	312 0.8×	459 1.3×	139 0.6×	47	1.5k
Michael Mac Manus Australia	12	375 0.5×	283 0.6×	205 0.5×	154 0.4×	341 1.5×	20	777
James D. Kolker United States	11	414 0.5×	167 0.3×	190 0.5×	94 0.3×	100 0.4×	20	580
Rachit Kumar United States	17	326 0.4×	354 0.7×	176 0.5×	90 0.3×	119 0.5×	50	724
Banu Atalar Türkiye	13	485 0.6×	193 0.4×	201 0.5×	188 0.5×	187 0.8×	64	718
Athanasios Colonias United States	15	554 0.7×	205 0.4×	260 0.7×	92 0.3×	192 0.8×	61	762
Cristina Mantovani Italy	16	562 0.7×	141 0.3×	375 1.0×	51 0.1×	249 1.1×	32	800
Marianne Marquard Knap Denmark	20	573 0.8×	199 0.4×	468 1.2×	72 0.2×	407 1.7×	56	955
Gianfranco Pesce Switzerland	16	278 0.4×	227 0.4×	142 0.4×	150 0.4×	116 0.5×	30	692

Countries citing papers authored by J. Praag

Since Specialization

Citations

This map shows the geographic impact of J. Praag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Praag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Praag more than expected).

Fields of papers citing papers by J. Praag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Praag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Praag. The network helps show where J. Praag may publish in the future.

Co-authorship network of co-authors of J. Praag

This figure shows the co-authorship network connecting the top 25 collaborators of J. Praag. A scholar is included among the top collaborators of J. Praag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Praag. J. Praag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zeng, Haiyan, Lizza Hendriks, Harry J.M. Groen, et al.. (2023). Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 study. Radiotherapy and Oncology. 183. 109627–109627. 5 indexed citations

Peeters, Stéphanie, Wouter van Elmpt, Alexander P.W.M. Maat, et al.. (2021). Optimal delineation of the clinical target volume for thymomas in the post-resection setting: A multi-center study. Radiotherapy and Oncology. 165. 8–13. 3 indexed citations

Baker, Sarah, Katerina Bakunina, Mischa S. Hoogeman, et al.. (2020). Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer. Radiation Oncology. 15(1). 89–89. 9 indexed citations

Ramaekers, Bram, Manuela Joore, Anne‐Marie C. Dingemans, et al.. (2019). Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study. Radiotherapy and Oncology. 144. 65–71. 11 indexed citations

Ruysscher, Dirk De, Anne‐Marie C. Dingemans, J. Praag, et al.. (2018). Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non–Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. Journal of Clinical Oncology. 36(23). 2366–2377. 75 indexed citations

Slotman, Ben J., Corinne Faivre‐Finn, Harm van Tinteren, et al.. (2017). Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer. 108. 150–153. 60 indexed citations

Ruysscher, Dirk De, Anne‐Marie C. Dingemans, J. Praag, et al.. (2017). MA 17.10 Toxicity Results from the Randomized Phase III NVALT-11 Study of Prophylactic Cranial Irradiation vs. Observation in Stage III NSCLC. Journal of Thoracic Oncology. 12(11). S1874–S1875. 2 indexed citations

Aluwini, Shafak, Wendimagegn Alemayehu, Joost L. Boormans, et al.. (2015). Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. Radiotherapy and Oncology. 117(2). 252–257. 19 indexed citations

Aluwini, Shafak, et al.. (2015). Long-term Treatment Outcome of Local Recurrences After Bladder Preservation With Brachytherapy for Bladder Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 93(3). E216–E217. 2 indexed citations

10.

Slotman, Ben J., Harm van Tinteren, J. Praag, et al.. (2014). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. The Lancet. 385(9962). 36–42. 384 indexed citations breakdown →

11.

Slotman, Ben J., Corinne Faivre‐Finn, Harm van Tinteren, et al.. (2014). International Multicenter Randomized Study on Thoracic Radiation Therapy (RT) in Extensive Stage Small Cell Lung Cancer (ES-SCLC): Patterns of Disease Recurrence. International Journal of Radiation Oncology*Biology*Physics. 90(1). S3–S4. 1 indexed citations

12.

Slotman, Ben J., Corinne Faivre‐Finn, Harm van Tinteren, et al.. (2014). Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer.. Journal of Clinical Oncology. 32(15_suppl). 7502–7502. 2 indexed citations

13.

Nuyttens, Joost J., Noëlle C. van der Voort van Zyp, J. Praag, et al.. (2012). Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiotherapy and Oncology. 102(3). 383–387. 86 indexed citations

14.

Aluwini, Shafak, Wim J. Kirkels, Peter P. Jansen, et al.. (2012). High-Dose-Rate Brachytherapy and External-Beam Radiotherapy for Hormone-Naïve Low- and Intermediate-Risk Prostate Cancer: A 7-Year Experience. International Journal of Radiation Oncology*Biology*Physics. 83(5). 1480–1485. 31 indexed citations

15.

Surmont, Veerle, Egbert F. Smit, Maja J.A. de Jonge, et al.. (2010). Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: Results from 2 phase I studies. Lung Cancer. 69(3). 302–306. 14 indexed citations

16.

Zyp, Noëlle C. van der Voort van, Jean‐Briac Prévost, Mischa S. Hoogeman, et al.. (2009). Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome. Radiotherapy and Oncology. 91(3). 296–300. 159 indexed citations

17.

Aluwini, Shafak, et al.. (2009). 70 oral: Clinical Outcome of Interstitial High Dose Rate (HDR) Brachytherapy + External Beam Radiotherapy (EBRT) for Early Stage Prostate Cancer. Radiotherapy and Oncology. 91. S24–S25. 1 indexed citations

18.

Prévost, Jean‐Briac, P. Voet, Mischa S. Hoogeman, et al.. (2008). Four-dimensional Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer: A Comparative Planning Study. Technology in Cancer Research & Treatment. 7(1). 27–33. 18 indexed citations

19.

Seppenwoolde, Yvette, Inger‐Karine K. Kolkman‐Deurloo, Dick Sipkema, et al.. (2007). HDR prostate monotherapy – Dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiotherapy and Oncology. 86(1). 114–119. 29 indexed citations

20.

Nuyttens, Joost J., J. Praag, Mischa S. Hoogeman, et al.. (2006). Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: Marker placement and early results. Acta Oncologica. 45(7). 961–965. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact